New hope for FSGS: experimental drug APL2 enters Late-Stage trial
NCT ID NCT07213960
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 22 times
Summary
This study tests a drug called APL2 for people with a kidney disease called FSGS, which causes protein leakage in urine and can lead to kidney failure. The trial has two parts: first, adults receive APL2 to see if it works; then, adults and teens are randomly assigned to get APL2 or a placebo to confirm its effects. The main goal is to reduce protein levels in urine, a sign of kidney damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FSGS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigator Site 1
Chicago, Illinois, 60643, United States
-
Investigator Site 2
New York, New York, 10032, United States
Conditions
Explore the condition pages connected to this study.